Abstract
The in vitro activities of LY333328 were compared with those of vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. MICs and MBCs were determined by a microtiter dilution protocol. LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Its potency was comparable or superior to those of other antibiotics tested against methicillin-resistant staphylococci.
Full Text
The Full Text of this article is available as a PDF (191.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arthur M., Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563–1571. doi: 10.1128/aac.37.8.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Collins L. A., Malanoski G. J., Eliopoulos G. M., Wennersten C. B., Ferraro M. J., Moellering R. C., Jr In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993 Mar;37(3):598–601. doi: 10.1128/aac.37.3.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hackbarth C. J., Chambers H. F. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrob Agents Chemother. 1989 Jul;33(7):995–999. doi: 10.1128/aac.33.7.995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayden M. K., Trenholme G. M., Schultz J. E., Sahm D. F. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis. 1993 May;167(5):1224–1227. doi: 10.1093/infdis/167.5.1224. [DOI] [PubMed] [Google Scholar]
- Inoue M., Okamoto R., Okubo T., Inoue K., Mitsuhashi S. Comparative in-vitro activity of RP 59500 against clinical bacterial isolates. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):45–51. doi: 10.1093/jac/30.suppl_a.45. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Sader H. S., Erwin M. E., Anderson S. C. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis. 1995 Feb;21(2):85–93. doi: 10.1016/0732-8893(94)00147-o. [DOI] [PubMed] [Google Scholar]
- Leclercq R., Nantas L., Soussy C. J., Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):67–75. doi: 10.1093/jac/30.suppl_a.67. [DOI] [PubMed] [Google Scholar]
- Low D. E., McGeer A., Poon R. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrob Agents Chemother. 1989 Apr;33(4):585–588. doi: 10.1128/aac.33.4.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nicas T. I., Mullen D. L., Flokowitsch J. E., Preston D. A., Snyder N. J., Stratford R. E., Cooper R. D. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob Agents Chemother. 1995 Nov;39(11):2585–2587. doi: 10.1128/aac.39.11.2585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schaberg D. R., Culver D. H., Gaynes R. P. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991 Sep 16;91(3B):72S–75S. doi: 10.1016/0002-9343(91)90346-y. [DOI] [PubMed] [Google Scholar]
- Schwalbe R. S., Ritz W. J., Verma P. R., Barranco E. A., Gilligan P. H. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis. 1990 Jan;161(1):45–51. doi: 10.1093/infdis/161.1.45. [DOI] [PubMed] [Google Scholar]